U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi will now charge Medicaid what they charge in other developed countries. New drugs made by those companies will also be charged at the so-called “most-favored-nation” pricing across the country, including commercial and cash pay markets as well as Medicare and Medicaid. Merck, GSK and Bristol Myers Squibb also agreed to donate significant supplies of active pharmaceutical ingredients to a national reserve.
